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Abstract
Vaccines are the sole preventative measure to eliminate poliomyelitis. The traditional biologic production in stainless steel bioreactors is limited by high capital expenditures and does not provide a
sustainable or cost-effective solution for the future. Univercells aims to change the paradigm and produce biologics using small-scale integrated systems, providing a more affordable and flexible
approach. The production of a polio vaccine candidate using this compact system paves the way for a worldwide production of affordable vaccines and biologics.
Conclusions
> The successful implementation of intensification and chaining for sIPV production led to a
drastically reduced equipment size, enabling the process to be operated within a closed system,
in a low footprint isolator, called micro-facility system, NevoLine.
> Thanks to improved recoveries, the intensified process achieves high productivity, delivering
525,000 doses of trivalent sIPV per batch.
> With Univercells NevoLine technology, viral vaccines such as polio can be produced in a
miniaturized fully-contained isolator for increased safety, leading to a tremendous impact on the
factory design, CAPEX and cost of manufacturing.
Perspectives
> Based on the successful implementation of the intensification and chaining concepts for sIPV, we
think NevoLine will provide tremendous value for many applications, like and without limitation:
i. Other viral vaccines for human and veterinary uses
ii. Rapid deployment manufacturing capacities to face outbreaks
iii. Production of gene vectors needed for the ever-increasing gene therapy segment
Acknowledgement: Univercells was awarded a grant by the Bill and Melinda Gate foundation to Develop Breakthrough Vaccine 
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Biologics for all
We notice an increasing demand for affordable biologics such as vaccines, a demand reinforced by the
continued efforts of global immunization campaigns.
In the case of poliomyelitis, a renewed global immunization effort is combining the use of the OPV and
IPV by producing a injected inactivated vaccine using attenuated strains.
Due to its high infectivity, Polio vaccine needs to be handled in highly contained environment to ensure
operators and environment safety. Facilities complying with GAP III safety levels being usually very
complex and expensive to build and operate, new technologies are called for to implement cost-effective
sIPV production facilities.
To circumvent the limitations of traditional bioproduction methods (eggs, cell factories or micro-beads),
Univercells envisioned a down-scaled high-performance production process, leading to low-footprint
infrastructures more affordable (CAPEX & OPEX) and flexible, whilst achieving high productivity of
vaccines.
Materials and methods
> Bench-scale fixed-bed bioreactor (scale-X™, surface: 2.4m² available for cells);
> Carriers made of 100% pure non-woven hydrophilized PET fibers;
> Vero cells grown serum containing media, infection in serum-free media;
> Sabin attenuated polio strains;
> Cell nuclei count on carriers estimated by crystal violet staining;
> Polio virus production estimated by ELISA assay (D-antigen content) and TCID50.
> Two steps purification (single step enhanced filtration & single step high affinity CEX chromatography)
> CoGs calculation using BioSolve 2017 (BioPharm Services)
Figure 1: NevoLine single-use manufacturing 
platform, and its containment in BSL3 POD & POD-
based facility
NevoLine™ micro-facility concept
Univercells designed a self-contained, single-use, closed, low footprint and automated continuous
manufacturing platform for GMP pilot and commercial-scale virus production (figure 1). Self-contained
upstream and downstream modules reduce the facility CAPEX, while reducing OPEX at the same time
through automation and downsized continuous processing.
The first application was developed with Bill and Melinda Gates Foundation funding to meet the goal of
reducing the cost of manufacturing inactivated attenuated polio vaccine to U.S. $0.15/dose, presented
here.
2. Cell growth & fixed-bed homogeneity
Cultivation of Vero cells in medium with serum was carried out in 2.4m² compact fixed-bed bioreactors
achieving high cell density. Cell dispersion results show homogeneity in the fixed bed, ensuring even and
predictable growth throughout the structure (figure 4). Thanks to its unique compact structure, scale-X
bioreactors seeded with cell densities a quarter of that needed for traditional systems grow nearly 50-fold to
reach a final concentration of 200,000+ cells / cm² (figure 3).
4. Productivity
The process was developed on the three strains of sIPV, achieving
promising productivity and purity results (table 1). The overall
process achieves high productivity, delivering an equivalent of 0,5
million doses of trivalent at 600m² scale (based on a ratio S1/S2/S3).
Serotype Doses / batch
PV1 ~6.8M
PV2 ~0.8M
PV3 ~2.0M
5. CoGs
Based on the process data obtained thus far (table 1), CoGs calculations of trivalent sIPV production were
performed using BioSolve software. Results achieved at small scale thus far predict a drug product Cost of
Goods close to reaching the BMGF target of <$0.15 / dose, to be attained with further process development
and optimization of operations both to increase the cell lines productivities and the DSP yields.
Results
1. Process flow chart
To deliver a low-footprint production unit, Univercells designed a complete sIPV production process of
small enough volume & footprint to fit into an isolator (figure 2), based on intensification and chaining
technologies.
# trivalent doses / year 43M
# doses / batch 525,000
# microfacilities 4
Production CAPEX $13M
# batches / year 88 (22 / microfacility)
3. Purification
First steps of purification, i.e. DNA removal step, pH adjustment and clarification, are performed in-line with
positive results. In-line single step purification using CEX chemistry participates in improving overall
downstream processing recovery yield & high purity.
Results of downstream processing steps for PV2 & PV3 demonstrate good overall yield, maintaining high
product purity (results for PV1 are being generated):
- HC-DNA concentration after CEX meets WHO requirements (spec <100pg DNA/dose)
- Total protein concentration either meets (PV2) or is very close to (PV3) WHO requirements (spec <0.1 µg
TP/DU).
Table 1: Overall process 
productivity at 600m² scale
Table 2: Estimated annual productivity of trivalent 
sIPV, using 600m² scale
Figure 2: Flow-chart of sIPV production in micro-facility
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Figure 4: Fixed-bed vertical dispersion 
in scale-X bioreactor
Figure 3: Growth of Vero cells cultivated in 
scale-X bioreactor (2.4m²)
(Two sets of experiments in two labs)
